Where is REGENXBIO headquartered?

REGENXBIO is located in Rockville, MD.

Who invested in REGENXBIO?

REGENXBIO has 13 investors including Geekdom Fund And Geekdom Fund.

When was the last funding round for REGENXBIO?

REGENXBIO closed its lastf unding roundon Jul 19, 2017 from a Convertible Note round.

Company Information
Company Timeline (Coming Soon)

regenxbio.com

REGENXBIO

REGENXBIO research and develops adeno-associated viral gene therapies for treatment of lysosomal storage disorders and ocular diseases.

Business Model:

Revenue: $483.4M

Employees: 201-500

Geographic Data

Address: 9804 Medical Center Drive

City: Rockville

State: MD

Zip: 20850

Country: US

Financial Info

Stage:

post ipo equity

Raised Last:

$230M

Raised Total:

$244M

Social

Facebook

Twitter

Crunchbase

Metrics

2,489,206Website Global Rank

7,258Website Monthly Traffic

Twitter Followers

Description

REGENXBIO research and develops adeno-associated viral gene therapies for treatment of lysosomal storage disorders and ocular diseases.

Contact Phone:
+12405528181

Contact Email:

IPO Details

REGENXBIO went public on 9/8/2015 on the NASDAQ

Listed Exchange:
NASDAQ

IPO Date:
9/8/2015

IPO Valuation:
$492M

Ticker Symbol:
RGNX

IPO Price:
$22/share

Amount Raised:
$138M

Live

Opened: -/share

EBITDA	-
Total Cash	-
Total Debt	-
Total Revenue	-
Total Profit (Gross)	-
PE Ratio	-

Investments

Announced Date	Company	Transaction	Money Raised

Funding Rounds

Announced Date	Transaction	Number of Investors	Money Raised	Lead Investors
11/2013	Venture Round	1	$7.9M	Eight Roads Ventures
3/2017	Post-IPO Equity		$87.2M
5/2011	Grant	1	$2.8M	National Institutes of Health
1/2021	Post-IPO Equity		$230.3M
8/2018	Post-IPO Equity		$201.8M
3/2013	Grant	2	$7.7M	EASME - EU Executive Agency for SMEs Fondazione Telethon
5/2015	Series D		$0	RTW Investments Foresite Capital Perceptive Advisors Sectoral Asset Management Venrock Cormorant Asset Management QVT Financial F-Prime Capital Tourbillon Global Ventures Vivo Capital Brookside Capital Janus Capital Group Jennison Associates RTW Investments Foresite Capital Perceptive Advisors Sectoral Asset Management Venrock Cormorant Asset Management QVT Financial F-Prime Capital Tourbillon Global Ventures Vivo Capital Brookside Capital Janus Capital Group Jennison Associates
1/2020	Post-IPO Equity	1	-	Frazier Healthcare Partners Frazier Healthcare Partners
5/2015	Series D		$70.5M	Vivo Capital Venrock Brookside Capital Jennison Associates LLC QVT Financial Sectoral Asset Management
1/2015	Series C	4	$30M	Brookside Capital Venrock F-Prime Capital Deepfield Brookside Capital Venrock
1/2015	Series C		$27.5M	Venrock Brookside Capital Deerfield Capital Management
9/2015	IPO		$138.6M
10/2013	Equity		$7.9M
1/2020	Post-IPO Equity	1	-	Frazier Healthcare Partners Frazier Healthcare Partners
5/2015	Series D	14	$70.5M	RTW Investments LLC Foresite Capital Perceptive Advisors Sectoral Asset Management Venrock Cormorant Asset Management QVT Financial F-Prime Capital Tourbillon Global Ventures Vivo Capital RTW Investments LLC Foresite Capital Perceptive Advisors Sectoral Asset Management Venrock Cormorant Asset Management QVT Financial F-Prime Capital Tourbillon Global Ventures Vivo Capital

Acquisitions

Announced Date	Name	Price
8/2017	Dimension Therapeutics

Employee Demographics

Employee Departments

Employee States

Similar Companies

Uniview Singapore VEID	Revenue: 0 - 100000 Employees: Industry: Software	Details
Konkuk University Medical Center	Revenue: 0 - 100000 Employees: 51 - 500 Industry: Education	Details
Daemon Technologies	Revenue: 0 - 100000 Employees: 1 - 10 Industry: Blockchain	Details
Ace International Trade	Revenue: 0 - 100000 Employees: 11 - 50 Industry: Industrial	Details
An Hòa Communications	Revenue: 0 - 100000 Employees: 1 - 10 Industry: Advertising	Details